A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
Cedars Sinai Medical Center, Los Angeles, California Dana Farber Cancer Institute, Boston, Massachusetts University of Michigan, Ann Arbor, Michigan Tennessee Oncology, Nashville, Tennessee Mary Crowley Cancer Research, Dallas, Texas University of Texas Southwestern Medical Center, Dallas, Texas MD Anderson Cancer Center, Houston, Texas Canada
Princess Margaret Cancer Centre, Toronto, Ontario Last updated September 2025